Literature DB >> 24273137

The minimum important difference for the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form in women with stress urinary incontinence.

Larry T Sirls1, Sharon Tennstedt, Linda Brubaker, Hae-Young Kim, Ingrid Nygaard, David D Rahn, Jonathan Shepherd, Holly E Richter.   

Abstract

INTRODUCTION: Minimum important difference (MID) estimates the minimum degree of change in an instrument's score that correlates with a patient's subjective sense of improvement. We aimed to determine the MID for the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) using both anchor based and distribution based methods derived using data from the Trial of Midurethral Slings (TOMUS).
MATERIALS AND METHODS: Instruments for the anchor-based analyses included the urogenital distress inventory (UDI), incontinence impact questionnaire (IIQ), patient global impression of improvement (PGI-I), incontinence episodes (IE) on 7-day bladder diary, and satisfaction with surgical results. After confirming moderate correlation (r ≥ 0.3) of ICIQ-UI SF and each anchor, MIDs were determined by calculating the difference between the mean instrument scores for individuals with the smallest amount of improvement and with no change. The distribution-based method of MID assessment was applied using effect sizes of 0.2 and 0.5 SD (small to medium effects). Triangulation was used to examine these multiple MID values in order to converge on a small range of values.
RESULTS: Anchor-based MIDs range from -4.5 to -5.7 at 12 months and from -3.1 to 4.3 at 24 months. Distribution-based MID values were lower. Triangulation analysis supports a MID of -5 at 12 months and -4 at 24 months.
CONCLUSION: The recommended MIDs for ICIQ-UI SF are -5 at 12 months and -4 at 24 months. In surgical patients, ICIQ-UI SF score changes that meet these thresholds can be considered clinically meaningful.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  ICIQ-UI SF; midurethral slin; minimum important difference; quality of life; urinary incontinence

Mesh:

Year:  2013        PMID: 24273137      PMCID: PMC4032375          DOI: 10.1002/nau.22533

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  14 in total

1.  Defining clinically meaningful change in health-related quality of life.

Authors:  Ross D Crosby; Ronette L Kolotkin; G Rhys Williams
Journal:  J Clin Epidemiol       Date:  2003-05       Impact factor: 6.437

Review 2.  Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes.

Authors:  Dennis Revicki; Ron D Hays; David Cella; Jeff Sloan
Journal:  J Clin Epidemiol       Date:  2007-08-03       Impact factor: 6.437

3.  Measurement of health status. Ascertaining the minimal clinically important difference.

Authors:  R Jaeschke; J Singer; G H Guyatt
Journal:  Control Clin Trials       Date:  1989-12

4.  An integrated method to determine meaningful changes in health-related quality of life.

Authors:  Ross D Crosby; Ronette L Kolotkin; G Rhys Williams
Journal:  J Clin Epidemiol       Date:  2004-11       Impact factor: 6.437

5.  The minimum important differences for the urinary scales of the Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire.

Authors:  Matthew D Barber; Cathie Spino; Nancy K Janz; Linda Brubaker; Ingrid Nygaard; Charles W Nager; Thomas L Wheeler
Journal:  Am J Obstet Gynecol       Date:  2009-05       Impact factor: 8.661

6.  ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence.

Authors:  Kerry Avery; Jenny Donovan; Tim J Peters; Christine Shaw; Momokazu Gotoh; Paul Abrams
Journal:  Neurourol Urodyn       Date:  2004       Impact factor: 2.696

7.  Condition-specific quality of life 24 months after retropubic and transobturator sling surgery for stress urinary incontinence.

Authors:  Larry T Sirls; Sharon Tennstedt; Emily Lukacz; Leslie Rickey; Stephen R Kraus; Alayne D Markland; Kimberly Kenton; Pam Moalli; Yvonne Hsu; Liyuan Huang; Anne M Stoddard
Journal:  Female Pelvic Med Reconstr Surg       Date:  2012 Sep-Oct       Impact factor: 2.091

8.  Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group.

Authors:  S A Shumaker; J F Wyman; J S Uebersax; D McClish; J A Fantl
Journal:  Qual Life Res       Date:  1994-10       Impact factor: 4.147

9.  Validity of patient-reported health-related quality of life global ratings of change using structural equation modeling.

Authors:  Stacie M Metz; Kathleen W Wyrwich; Ajit N Babu; Kurt Kroenke; William M Tierney; Fredric D Wolinsky
Journal:  Qual Life Res       Date:  2007-06-06       Impact factor: 4.147

10.  How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure.

Authors:  Jan L Brozek; Gordon H Guyatt; Holger J Schünemann
Journal:  Health Qual Life Outcomes       Date:  2006-09-27       Impact factor: 3.186

View more
  14 in total

1.  Comparing Vitamin D Supplementation Versus Placebo for Urgency Urinary Incontinence: A Pilot Study.

Authors:  Alayne D Markland; Vin Tangpricha; T Mark Beasley; Camille P Vaughan; Holly E Richter; Kathryn L Burgio; Patricia S Goode
Journal:  J Am Geriatr Soc       Date:  2018-12-21       Impact factor: 5.562

2.  The effect of pelvic floor muscle training and intravaginal electrical stimulation on urinary incontinence in women with incomplete spinal cord injury: an investigator-blinded parallel randomized clinical trial.

Authors:  Marlene Elmelund; Fin Biering-Sørensen; Ulla Due; Niels Klarskov
Journal:  Int Urogynecol J       Date:  2018-03-24       Impact factor: 2.894

3.  Analysis of Physical Therapy Intervention Outcomes for Urinary Incontinence in Women Older Than 65 Years in Outpatient Clinical Settings.

Authors:  Cynthia E Neville; Jason Beneciuk; Mark Bishop; Meryl Alappattu
Journal:  Top Geriatr Rehabil       Date:  2016 Oct-Dec

4.  Pre-rehabilitation of the pelvic floor before radiation therapy for cervical cancer: a pilot study.

Authors:  Cinara Sacomori; Paulina Araya-Castro; Paulette Diaz-Guerrero; Ingrid Alanis Ferrada; Angélica Claudia Martínez-Varas; Kamilla Zomkowski
Journal:  Int Urogynecol J       Date:  2020-06-29       Impact factor: 2.894

5.  A Comparative Analysis of Physiotherapy for Stress Urinary Incontinence after Open or Robotic-Assisted Radical Prostatectomy.

Authors:  Anika Sehgal; Richard Baverstock; Ian Wright; Candace Frey; Trafford Crump; Kevin Carlson
Journal:  Physiother Can       Date:  2019       Impact factor: 1.037

6.  Oncology Section EDGE Task Force on Urogenital Cancer: A Systematic Review of Clinical Measures for Incontinence.

Authors:  Alicia Jeffrey; Shana E Harrington; Alexandra Hill; Amanda Roscow; Meryl Alappattu
Journal:  Rehabil Oncol       Date:  2017-07

7.  Magnetic stimulation for stress urinary incontinence: study protocol for a randomized controlled trial.

Authors:  Renly Lim; Men Long Liong; Wing Seng Leong; Nurzalina Abdul Karim Khan; Kah Hay Yuen
Journal:  Trials       Date:  2015-06-21       Impact factor: 2.279

8.  Vaginal, sexual and urinary symptoms following hysterectomy: a multi-centre randomized controlled trial.

Authors:  Chanil Ekanayake; Arunasalam Pathmeswaran; Rasika Herath; Prasantha Wijesinghe
Journal:  Womens Midlife Health       Date:  2020-03-02

9.  Quality-of-Life Outcomes Following Surface Electromyography Biofeedback as an Adjunct to Pelvic Floor Muscle Training for Urinary Incontinence: A Case Report.

Authors:  Alexandra Hill; Meryl Alappattu
Journal:  J Womens Health Phys Therap       Date:  2017-05

10.  A new validated score for detecting patient-reported success on postoperative ICIQ-SF: a novel two-stage analysis from two large RCT cohorts.

Authors:  Debjyoti Karmakar; Alyaa Mostafa; Mohamed Abdel-Fattah
Journal:  Int Urogynecol J       Date:  2016-07-05       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.